Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to “Hold” at Citigroup

Regeneron Pharmaceuticals (NASDAQ:REGN) was upgraded by stock analysts at Citigroup to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

Several other brokerages also recently commented on REGN. Evercore ISI dropped their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Guggenheim increased their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. StockNews.com lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. BMO Capital Markets dropped their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, TD Cowen lifted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,097.14.

Regeneron Pharmaceuticals Stock Down 2.7 %

Shares of NASDAQ REGN opened at $782.51 on Wednesday. The company has a market cap of $85.99 billion, a price-to-earnings ratio of 19.36, a PEG ratio of 3.04 and a beta of 0.15. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12 month low of $780.95 and a 12 month high of $1,211.20. The stock has a 50-day moving average price of $1,000.06 and a two-hundred day moving average price of $1,035.67.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 7.48% of the stock is currently owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Paloma Partners Management Co raised its holdings in Regeneron Pharmaceuticals by 1,789.2% during the third quarter. Paloma Partners Management Co now owns 625 shares of the biopharmaceutical company’s stock worth $657,000 after buying an additional 662 shares during the last quarter. Kestra Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 48.1% during the third quarter. Kestra Investment Management LLC now owns 616 shares of the biopharmaceutical company’s stock worth $648,000 after acquiring an additional 200 shares in the last quarter. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $26,000. Erste Asset Management GmbH bought a new position in Regeneron Pharmaceuticals in the 3rd quarter valued at about $42,480,000. Finally, Caisse DE Depot ET Placement DU Quebec boosted its stake in Regeneron Pharmaceuticals by 40.2% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 194,625 shares of the biopharmaceutical company’s stock valued at $204,598,000 after purchasing an additional 55,828 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.